Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23451769,accumulation index,"Apixaban steady-state concentrations were reached by day 3, with an accumulation index of 1.3-1.9.","Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23451769/),,1.3-1.9,2347,DB06605,Apixaban
,33516188,flow rates,Linear regression was utilized to provide dosing estimations for flow rates from 0.5-5 L/h.,Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33516188/),[l] / [h],0.5-5,7672,DB06605,Apixaban
,33516188,adsorption,"Mean adsorption to the HF1400 and M150 filters differed significantly at 38 and 13%, respectively, while mean (± standard deviation, SD) percent protein binding was 70.81 ± 0.01%.",Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33516188/),%,38,7673,DB06605,Apixaban
,33516188,adsorption,"Mean adsorption to the HF1400 and M150 filters differed significantly at 38 and 13%, respectively, while mean (± standard deviation, SD) percent protein binding was 70.81 ± 0.01%.",Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33516188/),%,13,7674,DB06605,Apixaban
,33516188,percent protein binding,"Mean adsorption to the HF1400 and M150 filters differed significantly at 38 and 13%, respectively, while mean (± standard deviation, SD) percent protein binding was 70.81 ± 0.01%.",Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33516188/),%,70.81,7675,DB06605,Apixaban
,33516188,flow rates,"Linear regression revealed significant effects of filter type and flow rate on CLTM by AUC, suggesting doses of 2.5-7.5 mg twice daily (BID) may be needed for flow rates ranging from 0.5-5 L/h, respectively.",Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33516188/),[l] / [h],0.5-5,7676,DB06605,Apixaban
,23535530,half-life,"Apixaban has a half-life of about 12 hours, and the normal dosage is 5 mg orally twice daily.",Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23535530/),h,12,8513,DB06605,Apixaban
,30411284,Elimination half-lives,Elimination half-lives could be estimated in eight patients and ranged between 14.6 and 59.7 h (median 21.6).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,21.6,22073,DB06605,Apixaban
,30411284,waiting time for,The observed waiting time for surgery was longer for patients using DOACs than warfarin (median 44 vs. 25 h).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,44,22074,DB06605,Apixaban
,30411284,waiting time for,The observed waiting time for surgery was longer for patients using DOACs than warfarin (median 44 vs. 25 h).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,25,22075,DB06605,Apixaban
,33278889,blood concentration,Apixaban blood concentration increased up to 1712 μg/L at H + 6 (1000-2750 μg/L using 2-5 mg/kg of apixaban in adults).,Accidental apixaban intoxication in a 23-month-old child: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33278889/),,1000-2750,23553,DB06605,Apixaban
,33278889,terminal half-life,The terminal half-life was 8.2 h (6-15 h in adults).,Accidental apixaban intoxication in a 23-month-old child: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33278889/),h,8.2,23554,DB06605,Apixaban
,21318583,inhibitory constant,"With an inhibitory constant of 0.08 nM for human FXa, apixaban has greater than 30,000-fold selectivity for FXa over other human coagulation proteases.","Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21318583/),nM,0.08,24193,DB06605,Apixaban
,21318583,association rate constant,It produces a rapid onset of inhibition of FXa with association rate constant of 20 μM⁻¹/s approximately and inhibits free as well as prothrombinase- and clot-bound FXa activity in vitro.,"Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21318583/),[μM⁻¹] / [s],20,24194,DB06605,Apixaban
,29457840,CL/F,The population mean of CL/F for a typical patient (Ccr value of 70 ml min-1 ) with the CYP3A5*1/*1 and ABCG2 421C/C or C/A genotypes was estimated to be 3.06 l h-1 .,Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29457840/),[l] / [h],3.06,28742,DB06605,Apixaban
,29457840,Vd/F,The population mean of Vd/F was estimated to be 24.7 l.,Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29457840/),l,24.7,28743,DB06605,Apixaban
,26188837,Frel,"Frel of the oral solution was 105% versus tablet, and Frel for oral solution via NGT with D5W flush, infant formula flush, nutritional supplement, and crushed tablet via NGT versus oral solution administration were 96.7%, 92.2%, 81.3%, and 95.1%, respectively.",Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26188837/),%,105,40771,DB06605,Apixaban
,26188837,Frel,"Frel of the oral solution was 105% versus tablet, and Frel for oral solution via NGT with D5W flush, infant formula flush, nutritional supplement, and crushed tablet via NGT versus oral solution administration were 96.7%, 92.2%, 81.3%, and 95.1%, respectively.",Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26188837/),%,96.7,40772,DB06605,Apixaban
,26188837,Frel,"Frel of the oral solution was 105% versus tablet, and Frel for oral solution via NGT with D5W flush, infant formula flush, nutritional supplement, and crushed tablet via NGT versus oral solution administration were 96.7%, 92.2%, 81.3%, and 95.1%, respectively.",Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26188837/),%,92.2,40773,DB06605,Apixaban
,26188837,Frel,"Frel of the oral solution was 105% versus tablet, and Frel for oral solution via NGT with D5W flush, infant formula flush, nutritional supplement, and crushed tablet via NGT versus oral solution administration were 96.7%, 92.2%, 81.3%, and 95.1%, respectively.",Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26188837/),%,81.3,40774,DB06605,Apixaban
,26188837,Frel,"Frel of the oral solution was 105% versus tablet, and Frel for oral solution via NGT with D5W flush, infant formula flush, nutritional supplement, and crushed tablet via NGT versus oral solution administration were 96.7%, 92.2%, 81.3%, and 95.1%, respectively.",Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26188837/),%,95.1,40775,DB06605,Apixaban
,29977164,terminal half-life,"Betrixaban has the longest half-life among the DOAC class, with a terminal half-life of 35-45 h and an effective half-life of 19-27 h.",Pharmacological properties of betrixaban. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29977164/),h,35-45,53299,DB06605,Apixaban
,29977164,effective half-life,"Betrixaban has the longest half-life among the DOAC class, with a terminal half-life of 35-45 h and an effective half-life of 19-27 h.",Pharmacological properties of betrixaban. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29977164/),h,19-27,53300,DB06605,Apixaban
,31464657,elimination half-life,Clinical work-up did not confirm ischemic or hemorrhagic stroke but routine quantification of apixaban revealed an excessively high apixaban plasma concentration (~ 3 h after the last drug intake: 1100 ng/ml (expected range: 91-321 ng/ml); ~ 12 h after drug intake: 900 ng/ml (expected range: 41-230 ng/ml)) and a substantially prolonged elimination half-life (~ 31 h).,Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31464657/),h,31,59171,DB06605,Apixaban
,31464657,concentration-to-dose ratio,"The corresponding apixaban concentration-to-dose ratio was 9900 (ng/ml)/(mg/kg/d) and 8100 (ng/ml)/(mg/kg/d), respectively (expected range: 249-463 (ng/ml)/(mg/kg/d)).",Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31464657/),[ml·ng] / [d·kg·mg],9900,59172,DB06605,Apixaban
,31464657,concentration-to-dose ratio,"The corresponding apixaban concentration-to-dose ratio was 9900 (ng/ml)/(mg/kg/d) and 8100 (ng/ml)/(mg/kg/d), respectively (expected range: 249-463 (ng/ml)/(mg/kg/d)).",Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31464657/),[ml·ng] / [d·kg·mg],8100,59173,DB06605,Apixaban
exceeded,29055248,Extraction recoveries,Extraction recoveries exceeded 80 %.,Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055248/),%,80,60787,DB06605,Apixaban
,30564584,elimination half-life,"The elimination half-life was 1.3 ± 0.2 h, with high protein binding (92-99%).",Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564584/),h,1.3,84957,DB06605,Apixaban
,30564584,protein binding,"The elimination half-life was 1.3 ± 0.2 h, with high protein binding (92-99%).",Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564584/),%,92-99,84958,DB06605,Apixaban
,33948767,zeta potential,"API-ETHO2 was spherical with an average size of 145.1±12.3 nm, zeta potential of -20±4 mV, entrapment efficiency of 67.11%±3.26, and in vitro % release of 79.54%±4.1.","Intranasal In Situ Gel of Apixaban-Loaded Nanoethosomes: Preparation, Optimization, and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948767/),mv,-20,85455,DB06605,Apixaban
,33948767,entrapment efficiency,"API-ETHO2 was spherical with an average size of 145.1±12.3 nm, zeta potential of -20±4 mV, entrapment efficiency of 67.11%±3.26, and in vitro % release of 79.54%±4.1.","Intranasal In Situ Gel of Apixaban-Loaded Nanoethosomes: Preparation, Optimization, and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948767/),%,67.11,85456,DB06605,Apixaban
,33948767,% release,"API-ETHO2 was spherical with an average size of 145.1±12.3 nm, zeta potential of -20±4 mV, entrapment efficiency of 67.11%±3.26, and in vitro % release of 79.54%±4.1.","Intranasal In Situ Gel of Apixaban-Loaded Nanoethosomes: Preparation, Optimization, and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948767/),%,79.54,85457,DB06605,Apixaban
,33948767,permeation,Apixaban ethosomal in situ gel evolved higher ex vivo permeation (1.499±0.11 μg/cm2h) through the nasal mucosa than pure apixaban gel.,"Intranasal In Situ Gel of Apixaban-Loaded Nanoethosomes: Preparation, Optimization, and In Vivo Evaluation. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948767/),[μg] / [cm2h],1.499,85458,DB06605,Apixaban
,27436437,initial,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86365,DB06605,Apixaban
,27436437,peak apixaban concentration,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86366,DB06605,Apixaban
,27436437,elimination half-life,Apixaban elimination appeared to display first-order kinetics with an elimination half-life of 7.4 h.,Anti-Xa activity in apixaban overdose: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),h,7.4,86367,DB06605,Apixaban
,25419161,time-to-maximum concentration,"Median time-to-maximum concentration was 2 hours for both compounds, and the mean half-life was 8.7 and 7.9 hours for apixaban and rivaroxaban, respectively.",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),h,2,94072,DB06605,Apixaban
,25419161,half-life,"Median time-to-maximum concentration was 2 hours for both compounds, and the mean half-life was 8.7 and 7.9 hours for apixaban and rivaroxaban, respectively.",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),h,8.7,94073,DB06605,Apixaban
,25419161,half-life,"Median time-to-maximum concentration was 2 hours for both compounds, and the mean half-life was 8.7 and 7.9 hours for apixaban and rivaroxaban, respectively.",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),h,7.9,94074,DB06605,Apixaban
,25419161,area under the curve (AUC(0-24)),"Daily exposure, the area under the curve (AUC(0-24)), appeared similar for rivaroxaban (1,094 ng · h/mL) and apixaban (935 ng · h/mL), whereas mean peak-to-trough plasma concentration ratio was 3.6-fold greater for rivaroxaban (16.9) than apixaban (4.7).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[h·ng] / [ml],"1,094",94075,DB06605,Apixaban
,25419161,area under the curve (AUC(0-24)),"Daily exposure, the area under the curve (AUC(0-24)), appeared similar for rivaroxaban (1,094 ng · h/mL) and apixaban (935 ng · h/mL), whereas mean peak-to-trough plasma concentration ratio was 3.6-fold greater for rivaroxaban (16.9) than apixaban (4.7).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[h·ng] / [ml],935,94076,DB06605,Apixaban
,25419161,peak-to-trough plasma concentration ratio,"Daily exposure, the area under the curve (AUC(0-24)), appeared similar for rivaroxaban (1,094 ng · h/mL) and apixaban (935 ng · h/mL), whereas mean peak-to-trough plasma concentration ratio was 3.6-fold greater for rivaroxaban (16.9) than apixaban (4.7).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),,16.9,94077,DB06605,Apixaban
,25419161,peak-to-trough plasma concentration ratio,"Daily exposure, the area under the curve (AUC(0-24)), appeared similar for rivaroxaban (1,094 ng · h/mL) and apixaban (935 ng · h/mL), whereas mean peak-to-trough plasma concentration ratio was 3.6-fold greater for rivaroxaban (16.9) than apixaban (4.7).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),,4.7,94078,DB06605,Apixaban
,25419161,Trough concentrations,"Trough concentrations and AXA were lower for rivaroxaban (10 ng/mL and 0.17 IU/mL vs 17 ng/mL and 0.24 IU/mL for apixaban, respectively).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[ng] / [ml],10,94079,DB06605,Apixaban
,25419161,Trough concentrations,"Trough concentrations and AXA were lower for rivaroxaban (10 ng/mL and 0.17 IU/mL vs 17 ng/mL and 0.24 IU/mL for apixaban, respectively).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[iu] / [ml],0.17,94080,DB06605,Apixaban
,25419161,Trough concentrations,"Trough concentrations and AXA were lower for rivaroxaban (10 ng/mL and 0.17 IU/mL vs 17 ng/mL and 0.24 IU/mL for apixaban, respectively).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[ng] / [ml],17,94081,DB06605,Apixaban
,25419161,AXA,"Trough concentrations and AXA were lower for rivaroxaban (10 ng/mL and 0.17 IU/mL vs 17 ng/mL and 0.24 IU/mL for apixaban, respectively).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[iu] / [ml],0.17,94082,DB06605,Apixaban
,25419161,AXA,"Trough concentrations and AXA were lower for rivaroxaban (10 ng/mL and 0.17 IU/mL vs 17 ng/mL and 0.24 IU/mL for apixaban, respectively).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[iu] / [ml],0.24,94083,DB06605,Apixaban
,19851712,oral bioavailability (F,"Rabbits are commonly used in development of thrombosis disease models; however, unlike in other species, apixaban demonstrated poor oral bioavailability (F = 3%) and a high clearance rate (2.55 l/h/kg) in rabbits.","Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19851712/),%,3,96313,DB06605,Apixaban
,19851712,clearance rate,"Rabbits are commonly used in development of thrombosis disease models; however, unlike in other species, apixaban demonstrated poor oral bioavailability (F = 3%) and a high clearance rate (2.55 l/h/kg) in rabbits.","Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19851712/),[l] / [h·kg],2.55,96314,DB06605,Apixaban
,19851712,concentration required,The apixaban concentration required for 50% inhibition (IC50) of FXa activity ex vivo (0.22 +/- 0.02 microM) agreed with the IC50 from in vitro experiments in rabbit and human plasma.,"Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19851712/),μM,0.22,96315,DB06605,Apixaban
,19851712,50% inhibition (IC50),The apixaban concentration required for 50% inhibition (IC50) of FXa activity ex vivo (0.22 +/- 0.02 microM) agreed with the IC50 from in vitro experiments in rabbit and human plasma.,"Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19851712/),μM,0.22,96316,DB06605,Apixaban
,27116356,flow rate,"The analytes and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1 mm × 50 mm, 1.7 μm) using gradient elution with a mobile phase of acetonitrile and 0.1 % formic acid in water at a flow rate of 0.4 mL/min.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),[ml] / [min],0.4,100915,DB06605,Apixaban
,27116356,m/,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,460.0,100916,DB06605,Apixaban
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,548.2,100917,DB06605,Apixaban
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,366.1,100918,DB06605,Apixaban
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,285.2,100919,DB06605,Apixaban
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,193.1,100920,DB06605,Apixaban
,27116356,Total time,Total time for each chromatograph was 3.5 min.,"Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),min,3.5,100921,DB06605,Apixaban
,28302754,area under the concentration-time curve from 0 to 24 hours,The area under the concentration-time curve from 0 to 24 hours increased from 628 to 2054 ng h/ml (P<0.001).,Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302754/),[h·ng] / [ml],628 to 2054,101998,DB06605,Apixaban
,28302754,Trough levels,Trough levels increased from 45 to 132 ng/ml (P<0.001).,Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302754/),[ng] / [ml],45 to 132,101999,DB06605,Apixaban
,28302754,area under the concentration-time curve,"The area under the concentration-time curve further increased to 6045 ng h/ml (P=0.03), and trough levels increased to 218 ng/ml (P=0.03), above the 90th percentile for the 5-mg dose in patients with preserved renal function.",Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302754/),[h·ng] / [ml],6045,102000,DB06605,Apixaban
,28302754,trough levels,"The area under the concentration-time curve further increased to 6045 ng h/ml (P=0.03), and trough levels increased to 218 ng/ml (P=0.03), above the 90th percentile for the 5-mg dose in patients with preserved renal function.",Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302754/),[ng] / [ml],218,102001,DB06605,Apixaban
,29296829,terminal elimination half-life,"Andexanet plasma concentration increased proportionally with dose, with rapid elimination (terminal elimination half-life, 4.35-7.5 hours).","Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29296829/),h,4.35-7.5,104598,DB06605,Apixaban
,34046920,maximum concentration,"Oral administration yielded a mean maximum concentration of 60.3 ng/ml (59.4-111 ng/ml), mean time to maximum concentration of 0.5 hr (0.5-2), mean half-life of 6.2 hr (4.6-8.3), and mean oral bioavailability of 10% (3.8-17.4).",Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34046920/),[ng] / [ml],60.3,107723,DB06605,Apixaban
,34046920,time to maximum concentration,"Oral administration yielded a mean maximum concentration of 60.3 ng/ml (59.4-111 ng/ml), mean time to maximum concentration of 0.5 hr (0.5-2), mean half-life of 6.2 hr (4.6-8.3), and mean oral bioavailability of 10% (3.8-17.4).",Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34046920/),h,0.5,107724,DB06605,Apixaban
,34046920,half-life,"Oral administration yielded a mean maximum concentration of 60.3 ng/ml (59.4-111 ng/ml), mean time to maximum concentration of 0.5 hr (0.5-2), mean half-life of 6.2 hr (4.6-8.3), and mean oral bioavailability of 10% (3.8-17.4).",Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34046920/),h,6.2,107725,DB06605,Apixaban
,34046920,oral bioavailability,"Oral administration yielded a mean maximum concentration of 60.3 ng/ml (59.4-111 ng/ml), mean time to maximum concentration of 0.5 hr (0.5-2), mean half-life of 6.2 hr (4.6-8.3), and mean oral bioavailability of 10% (3.8-17.4).",Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34046920/),%,10,107726,DB06605,Apixaban
,34046920,E0,"After oral administration, anti-Xa activity had a strong positive relationship with serum apixaban and was best represented by a dose-response model with the following parameters: E0 = 5.00 ng/ml, EMAX = 311 ng/mL, EC50 = 267 ng/ml, and n = 1.58.",Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34046920/),[ng] / [ml],5.00,107727,DB06605,Apixaban
,34046920,EMAX,"After oral administration, anti-Xa activity had a strong positive relationship with serum apixaban and was best represented by a dose-response model with the following parameters: E0 = 5.00 ng/ml, EMAX = 311 ng/mL, EC50 = 267 ng/ml, and n = 1.58.",Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34046920/),[ng] / [ml],311,107728,DB06605,Apixaban
,34046920,EC50,"After oral administration, anti-Xa activity had a strong positive relationship with serum apixaban and was best represented by a dose-response model with the following parameters: E0 = 5.00 ng/ml, EMAX = 311 ng/mL, EC50 = 267 ng/ml, and n = 1.58.",Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34046920/),[ng] / [ml],267,107729,DB06605,Apixaban
,32055579,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax) was 371.57 ng/mL, and the median time to achieve the Cmax (Tmax) was 4 h after administration of 10 mg apixaban alone.",Quantification of apixaban in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055579/),[ng] / [ml],371.57,121645,DB06605,Apixaban
,32055579,time to achieve the Cmax (Tmax),"The mean maximum plasma concentration (Cmax) was 371.57 ng/mL, and the median time to achieve the Cmax (Tmax) was 4 h after administration of 10 mg apixaban alone.",Quantification of apixaban in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055579/),h,4,121646,DB06605,Apixaban
,26749408,absolute oral bioavailability,Apixaban absolute oral bioavailability was 49 % when administered alone and 39 % following induction by rifampin.,"Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26749408/),%,49,122501,DB06605,Apixaban
,26749408,absolute oral bioavailability,Apixaban absolute oral bioavailability was 49 % when administered alone and 39 % following induction by rifampin.,"Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26749408/),%,39,122502,DB06605,Apixaban
,22759198,t(max),Median t(max) occurred 1.5-3.3 h following oral administration.,"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22759198/),h,1.5-3.3,124888,DB06605,Apixaban
,22759198,terminal half-life,Mean terminal half-life ranged between 3.6 and 6.8 h following administration of solution doses ≤2.5 mg and between 11.1 and 26.8 h for tablet doses ≥5 mg.,"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22759198/),h,3.6 and 6.8,124889,DB06605,Apixaban
,22759198,terminal half-life,Mean terminal half-life ranged between 3.6 and 6.8 h following administration of solution doses ≤2.5 mg and between 11.1 and 26.8 h for tablet doses ≥5 mg.,"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22759198/),h,11.1 and 26.8,124890,DB06605,Apixaban
,22759198,half-life,Apixaban half-life was approximately 11.5 h.,"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22759198/),h,11.5,124891,DB06605,Apixaban
,22759198,half-life,Single doses of apixaban were well tolerated with a predictable pharmacokinetic/pharmacodynamic profile and a half-life of approximately 12 h.,"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22759198/),h,12,124892,DB06605,Apixaban
,23466964,IC2x LT,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.10,132118,DB06605,Apixaban
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.063,132119,DB06605,Apixaban
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.18,132120,DB06605,Apixaban
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.50,132121,DB06605,Apixaban
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.55,132122,DB06605,Apixaban
,34155947,trough,"The median doseadjusted tacrolimus trough and tacrolimus total daily dose prior to rivaroxaban/apixaban initiation was 2.15 ng/mL/mg (IQR 1.17, 3.37) and 4 mg (IQR 1.88, 6.25), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),[ng] / [mg·ml],2.15,133517,DB06605,Apixaban
,34155947,total daily dose,"The median doseadjusted tacrolimus trough and tacrolimus total daily dose prior to rivaroxaban/apixaban initiation was 2.15 ng/mL/mg (IQR 1.17, 3.37) and 4 mg (IQR 1.88, 6.25), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),mg,4,133518,DB06605,Apixaban
,34155947,trough,"The median dose-adjusted tacrolimus trough and tacrolimus total daily dose after rivaroxaban/apixaban initiation was 2.16 ng/mL/mg (IQR 1.24, 4.10) and 3.55 mg (IQR 1.5, 6.35), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),[ng] / [mg·ml],2.16,133519,DB06605,Apixaban
,34155947,total daily dose,"The median dose-adjusted tacrolimus trough and tacrolimus total daily dose after rivaroxaban/apixaban initiation was 2.16 ng/mL/mg (IQR 1.24, 4.10) and 3.55 mg (IQR 1.5, 6.35), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),mg,3.55,133520,DB06605,Apixaban
,26842561,steady state peak,"Based on drug concentrations previously published in pharmacokinetic studies, the expected steady state peak and trough antifactor Xa activity ranges for apixaban are 1.80 to 2.20 IU/mL and 0.70 to 1.10 IU/mL, respectively.",Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26842561/),[iu] / [ml],1.80 to 2.20,137223,DB06605,Apixaban
,26842561,trough antifactor Xa activity,"Based on drug concentrations previously published in pharmacokinetic studies, the expected steady state peak and trough antifactor Xa activity ranges for apixaban are 1.80 to 2.20 IU/mL and 0.70 to 1.10 IU/mL, respectively.",Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26842561/),[iu] / [ml],0.70 to 1.10,137224,DB06605,Apixaban
,30421528,Cmax,"The Cmax was observed 17 h after the intake (3654 μg l-1 ), about four times the classical Tmax value (median [range]: 4 h [2-4]).","Self-poisoning with 60 tablets of Apixaban, a pharmacokinetics case report. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30421528/),[μg] / [l],3654,137654,DB06605,Apixaban
,30421528,Tmax,"The Cmax was observed 17 h after the intake (3654 μg l-1 ), about four times the classical Tmax value (median [range]: 4 h [2-4]).","Self-poisoning with 60 tablets of Apixaban, a pharmacokinetics case report. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30421528/),h,4,137655,DB06605,Apixaban
,30421528,half-life,The Apixaban was then eliminated following a first order elimination with a calculated half-life of 10.8 h.,"Self-poisoning with 60 tablets of Apixaban, a pharmacokinetics case report. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30421528/),h,10.8,137656,DB06605,Apixaban
,22177763,half-life,"The half-life is around 8 to 12 hours, with a peak activity 2 to 4 hours after ingestion.",[Pharmacologic heterogeneity of new anticoagulants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22177763/),h,8 to 12,148054,DB06605,Apixaban
,29472495,area under the concentration-time curve to the last sampling time (AUC0-12),"The area under the concentration-time curve to the last sampling time (AUC0-12) values for apixaban were not different between control and NAFLD subjects (671 and 545 ng/ml × hour, respectively; P = 0.15).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],671,185762,DB06605,Apixaban
,29472495,area under the concentration-time curve to the last sampling time (AUC0-12),"The area under the concentration-time curve to the last sampling time (AUC0-12) values for apixaban were not different between control and NAFLD subjects (671 and 545 ng/ml × hour, respectively; P = 0.15).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],545,185763,DB06605,Apixaban
,29472495,AUC0-12,"Similarly, the AUC0-12 values for rosuvastatin did not differ between the control and NAFLD groups (25.4 and 20.1 ng/ml × hour, respectively; P = 0.28).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],25.4,185764,DB06605,Apixaban
,29472495,AUC0-12,"Similarly, the AUC0-12 values for rosuvastatin did not differ between the control and NAFLD groups (25.4 and 20.1 ng/ml × hour, respectively; P = 0.28).",Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29472495/),[ng] / [h·ml],20.1,185765,DB06605,Apixaban
,21461793,absolute oral bioavailability,"Apixaban is well absorbed in rat, dog, and chimpanzee, with absolute oral bioavailability of approximately 50% or greater.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),%,50,190354,DB06605,Apixaban
,21461793,steady-state Vd,"The steady-state Vd of apixaban is approximately 0.5, 0.2, and 0.17 l/kg in rats, dogs, and chimpanzees, while CL is approximately 0.9, 0.04, and 0.018 l/h/kg, respectively.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),[l] / [kg],0.5,190355,DB06605,Apixaban
,21461793,steady-state Vd,"The steady-state Vd of apixaban is approximately 0.5, 0.2, and 0.17 l/kg in rats, dogs, and chimpanzees, while CL is approximately 0.9, 0.04, and 0.018 l/h/kg, respectively.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),[l] / [kg],0.2,190356,DB06605,Apixaban
,21461793,steady-state Vd,"The steady-state Vd of apixaban is approximately 0.5, 0.2, and 0.17 l/kg in rats, dogs, and chimpanzees, while CL is approximately 0.9, 0.04, and 0.018 l/h/kg, respectively.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),[l] / [kg],0.17,190357,DB06605,Apixaban
,21461793,CL,"The steady-state Vd of apixaban is approximately 0.5, 0.2, and 0.17 l/kg in rats, dogs, and chimpanzees, while CL is approximately 0.9, 0.04, and 0.018 l/h/kg, respectively.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),[l] / [h·kg],0.9,190358,DB06605,Apixaban
,21461793,CL,"The steady-state Vd of apixaban is approximately 0.5, 0.2, and 0.17 l/kg in rats, dogs, and chimpanzees, while CL is approximately 0.9, 0.04, and 0.018 l/h/kg, respectively.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),[l] / [h·kg],0.04,190359,DB06605,Apixaban
,21461793,CL,"The steady-state Vd of apixaban is approximately 0.5, 0.2, and 0.17 l/kg in rats, dogs, and chimpanzees, while CL is approximately 0.9, 0.04, and 0.018 l/h/kg, respectively.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),[l] / [h·kg],0.018,190360,DB06605,Apixaban
,21461793,IC(50),"The IC(50) values for anti-fXa activity were 0.73 ± 0.03 and 1.5 ± 0.15 μM for rat and dog, respectively.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),μM,0.73,190361,DB06605,Apixaban
,21461793,IC(50),"The IC(50) values for anti-fXa activity were 0.73 ± 0.03 and 1.5 ± 0.15 μM for rat and dog, respectively.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),μM,1.5,190362,DB06605,Apixaban
,21461793,apparent K ( i ),"The apparent K ( i ) values for PT were approximately 1.7, 6.6, and 4.8 μM for rat, dog and chimpanzee, respectively.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),μM,1.7,190363,DB06605,Apixaban
,21461793,apparent K ( i ),"The apparent K ( i ) values for PT were approximately 1.7, 6.6, and 4.8 μM for rat, dog and chimpanzee, respectively.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),μM,6.6,190364,DB06605,Apixaban
,21461793,apparent K ( i ),"The apparent K ( i ) values for PT were approximately 1.7, 6.6, and 4.8 μM for rat, dog and chimpanzee, respectively.","Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),μM,4.8,190365,DB06605,Apixaban
,21461793,apparent K ( i ),The apparent K ( i ) for HCT was approximately 1.3 μM for dog.,"Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21461793/),μM,1.3,190366,DB06605,Apixaban
,24353445,time to maximum concentration,"PK analysis showed similar characteristics of apixaban after single and multiple doses, including a median time to maximum concentration of ~3 hours, mean elimination half-life of ~11 hours, and renal clearance of ~1.2 L/hour.","Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24353445/),h,3,191168,DB06605,Apixaban
,24353445,elimination half-life,"PK analysis showed similar characteristics of apixaban after single and multiple doses, including a median time to maximum concentration of ~3 hours, mean elimination half-life of ~11 hours, and renal clearance of ~1.2 L/hour.","Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24353445/),h,11,191169,DB06605,Apixaban
,24353445,renal clearance,"PK analysis showed similar characteristics of apixaban after single and multiple doses, including a median time to maximum concentration of ~3 hours, mean elimination half-life of ~11 hours, and renal clearance of ~1.2 L/hour.","Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24353445/),[l] / [h],1.2,191170,DB06605,Apixaban
,24353445,accumulation index,"The accumulation index was 1.7, consistent with twice-daily dosing and the observed elimination half-life.","Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24353445/),,1.7,191171,DB06605,Apixaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,8,193385,DB06605,Apixaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,28,193386,DB06605,Apixaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,5,193387,DB06605,Apixaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,23,193388,DB06605,Apixaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,15,193389,DB06605,Apixaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,3,193390,DB06605,Apixaban
,30349887,peak concentrations,"The median peak concentrations (IQR) were 148 ng/mL (138-240), 138 ng/mL (123-156.5), 215 ng/mL (181-249) for apixaban, dabigatran, and rivaroxaban, respectively.",Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349887/),[ng] / [ml],148,199974,DB06605,Apixaban
,30349887,peak concentrations,"The median peak concentrations (IQR) were 148 ng/mL (138-240), 138 ng/mL (123-156.5), 215 ng/mL (181-249) for apixaban, dabigatran, and rivaroxaban, respectively.",Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349887/),[ng] / [ml],138,199975,DB06605,Apixaban
,30349887,peak concentrations,"The median peak concentrations (IQR) were 148 ng/mL (138-240), 138 ng/mL (123-156.5), 215 ng/mL (181-249) for apixaban, dabigatran, and rivaroxaban, respectively.",Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349887/),[ng] / [ml],215,199976,DB06605,Apixaban
,32160801,steady-state areas under the curve,"Median daily steady-state areas under the curve for apixaban 5 mg twice daily were 5512 ng/(mL·h) and 3406 ng/(mL·h) for patients with CrCl 25 to 30 mL/min or >30 mL/min, respectively.",Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32160801/),[ng] / [h·ml],5512,200286,DB06605,Apixaban
,32160801,steady-state areas under the curve,"Median daily steady-state areas under the curve for apixaban 5 mg twice daily were 5512 ng/(mL·h) and 3406 ng/(mL·h) for patients with CrCl 25 to 30 mL/min or >30 mL/min, respectively.",Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32160801/),[ng] / [h·ml],3406,200287,DB06605,Apixaban
,32160801,exposure,"For apixaban 2.5 mg twice daily, the median exposure was 2780 ng/(mL·h) for patients with CrCl 25 to 30 mL/min.",Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32160801/),[ng] / [h·ml],2780,200288,DB06605,Apixaban
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,1.90,202533,DB06605,Apixaban
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,2.35,202534,DB06605,Apixaban
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,2.27,202535,DB06605,Apixaban
,34342172,oral bioavailability,"Apixaban had 66.2% oral bioavailability, dose-proportional exposure, 17 to 26 L steady-state volume of distribution, and 3.2 to 3.5 L/h total plasma clearance.","Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34342172/),%,66.2,203383,DB06605,Apixaban
,34342172,steady-state volume of distribution,"Apixaban had 66.2% oral bioavailability, dose-proportional exposure, 17 to 26 L steady-state volume of distribution, and 3.2 to 3.5 L/h total plasma clearance.","Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34342172/),l,17 to 26,203384,DB06605,Apixaban
,34342172,total plasma clearance,"Apixaban had 66.2% oral bioavailability, dose-proportional exposure, 17 to 26 L steady-state volume of distribution, and 3.2 to 3.5 L/h total plasma clearance.","Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34342172/),[l] / [h],3.2 to 3.5,203385,DB06605,Apixaban
,34342172,Renal clearance,Renal clearance was ≈27%.,"Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34342172/),%,27,203386,DB06605,Apixaban
,24725442,accumulation index,"A modest degree of accumulation was observed that was similar for all doses (accumulation index of 1.7 to 2.0), and renal clearance was consistent across doses (0.91 L/h - 1.07 L/h).","Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725442/),,1.7 to 2.0,208292,DB06605,Apixaban
,24725442,renal clearance,"A modest degree of accumulation was observed that was similar for all doses (accumulation index of 1.7 to 2.0), and renal clearance was consistent across doses (0.91 L/h - 1.07 L/h).","Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725442/),[l] / [-·1.07·h],0.91,208293,DB06605,Apixaban
,32053549,absolute recoveries,"For all 3 anticoagulants and corresponding isotopically labeled internal standards, the absolute recoveries were similar and consistent, with mean values of 93%-102%.","Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32053549/),%,93,209618,DB06605,Apixaban
,32053549,absolute recoveries,"For all 3 anticoagulants and corresponding isotopically labeled internal standards, the absolute recoveries were similar and consistent, with mean values of 93%-102%.","Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32053549/),%,102,209619,DB06605,Apixaban
,27884586,concentrations,Plasma apixaban concentrations were 2765.6 ng/ml at 14 hours post ingestion with a non-linear half life.,The X factor: Lack of bleeding after an acute apixaban overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27884586/),[ng] / [ml],2765.6,211372,DB06605,Apixaban
,24861792,time to peak level,"The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to low-molecular-weight heparins, with a time to peak level of 1-4 hours after oral administration, and a half-life between 5 and 14 hours.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),h,1-4,211970,DB06605,Apixaban
,24861792,half-life,"The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to low-molecular-weight heparins, with a time to peak level of 1-4 hours after oral administration, and a half-life between 5 and 14 hours.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),h,5 and 14,211971,DB06605,Apixaban
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,66,211972,DB06605,Apixaban
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,33,211973,DB06605,Apixaban
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,25,211974,DB06605,Apixaban
,34291105,half-life,"Following IV administration, mean half-life was 4.1 h, and volume of distribution was 177 ml/kg.",Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34291105/),h,4.1,213675,DB06605,Apixaban
,34291105,volume of distribution,"Following IV administration, mean half-life was 4.1 h, and volume of distribution was 177 ml/kg.",Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34291105/),[ml] / [kg],177,213676,DB06605,Apixaban
,34291105,bioavailability,"Following oral administration, mean bioavailability was 28.4%, lag time was 2 h, time to Cmax was 5 h and the apparent elimination half-life was 3.1 h.",Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34291105/),%,28.4,213677,DB06605,Apixaban
,34291105,lag time,"Following oral administration, mean bioavailability was 28.4%, lag time was 2 h, time to Cmax was 5 h and the apparent elimination half-life was 3.1 h.",Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34291105/),h,2,213678,DB06605,Apixaban
,34291105,time to Cmax,"Following oral administration, mean bioavailability was 28.4%, lag time was 2 h, time to Cmax was 5 h and the apparent elimination half-life was 3.1 h.",Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34291105/),h,5,213679,DB06605,Apixaban
,34291105,apparent elimination half-life,"Following oral administration, mean bioavailability was 28.4%, lag time was 2 h, time to Cmax was 5 h and the apparent elimination half-life was 3.1 h.",Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34291105/),h,3.1,213680,DB06605,Apixaban
,32007354,AUC,"The geometric mean AUC for the 0 to 24-h interval was 4550 ng h/mL for apixaban, 2710 ng h/mL for 15 mg QD rivaroxaban, and 1290 ng h/mL for 60 mg QD edoxaban.",Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32007354/),[h·ng] / [ml],4550,228919,DB06605,Apixaban
,32007354,AUC,"The geometric mean AUC for the 0 to 24-h interval was 4550 ng h/mL for apixaban, 2710 ng h/mL for 15 mg QD rivaroxaban, and 1290 ng h/mL for 60 mg QD edoxaban.",Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32007354/),[h·ng] / [ml],2710,228920,DB06605,Apixaban
,32007354,AUC,"The geometric mean AUC for the 0 to 24-h interval was 4550 ng h/mL for apixaban, 2710 ng h/mL for 15 mg QD rivaroxaban, and 1290 ng h/mL for 60 mg QD edoxaban.",Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32007354/),[h·ng] / [ml],1290,228921,DB06605,Apixaban
,24697979,anti-Xa activity,"Mean (standard deviation [SD]) anti-Xa activity at 3 h post-dose was approximately 60% higher following co-administration compared with apixaban alone, 4.4 [1.0] vs. 2.7 [0.7] IU ml(-1) , consistent with the apixaban concentration increase following co-administration.",Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697979/),[iu] / [ml],4.4,236981,DB06605,Apixaban
,24697979,anti-Xa activity,"Mean (standard deviation [SD]) anti-Xa activity at 3 h post-dose was approximately 60% higher following co-administration compared with apixaban alone, 4.4 [1.0] vs. 2.7 [0.7] IU ml(-1) , consistent with the apixaban concentration increase following co-administration.",Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697979/),[iu] / [ml],2.7,236982,DB06605,Apixaban
,24697979,bleeding time,"Mean [SD] bleeding time was higher following co-administration (9.1 [4.1] min) compared with either agent alone (5.8 [2.3] and 6.9 [2.6] min for apixaban and naproxen, respectively).",Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697979/),min,9.1,236983,DB06605,Apixaban
,24697979,bleeding time,"Mean [SD] bleeding time was higher following co-administration (9.1 [4.1] min) compared with either agent alone (5.8 [2.3] and 6.9 [2.6] min for apixaban and naproxen, respectively).",Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697979/),min,5.8,236984,DB06605,Apixaban
,24697979,bleeding time,"Mean [SD] bleeding time was higher following co-administration (9.1 [4.1] min) compared with either agent alone (5.8 [2.3] and 6.9 [2.6] min for apixaban and naproxen, respectively).",Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697979/),min,6.9,236985,DB06605,Apixaban
,22398784,peak pharmacodynamic effect,"Average peak pharmacodynamic effect, measured by anti-Xa activity, was 1.36 U/ml after administration of apixaban and was 0.42 U/ml after enoxaparin.","A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22398784/),[u] / [ml],1.36,238163,DB06605,Apixaban
,22398784,peak pharmacodynamic effect,"Average peak pharmacodynamic effect, measured by anti-Xa activity, was 1.36 U/ml after administration of apixaban and was 0.42 U/ml after enoxaparin.","A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22398784/),[u] / [ml],0.42,238164,DB06605,Apixaban
,30498375,C max,"Apixaban reached maximum concentrations (C max) 3-4 h postdose, with mean C max ranging from 52.5-485.0 to 44.8-494.3 ng/mL in Japanese and Caucasian subjects.",Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498375/),[ng] / [ml],52.5-485.0,243903,DB06605,Apixaban
,30498375,C max,"Apixaban reached maximum concentrations (C max) 3-4 h postdose, with mean C max ranging from 52.5-485.0 to 44.8-494.3 ng/mL in Japanese and Caucasian subjects.",Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498375/),[ng] / [ml],44.8-494.3,243904,DB06605,Apixaban
,30498375,half-life,"The mean half-life was ~8 and ~13 h and the renal clearance was 1.1 and 0.8 L/h in Japanese and Caucasian subjects, respectively.",Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498375/),h,8,243905,DB06605,Apixaban
,30498375,half-life,"The mean half-life was ~8 and ~13 h and the renal clearance was 1.1 and 0.8 L/h in Japanese and Caucasian subjects, respectively.",Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498375/),h,13,243906,DB06605,Apixaban
,30498375,renal clearance,"The mean half-life was ~8 and ~13 h and the renal clearance was 1.1 and 0.8 L/h in Japanese and Caucasian subjects, respectively.",Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498375/),[l] / [h],1.1,243907,DB06605,Apixaban
,30498375,renal clearance,"The mean half-life was ~8 and ~13 h and the renal clearance was 1.1 and 0.8 L/h in Japanese and Caucasian subjects, respectively.",Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498375/),[l] / [h],0.8,243908,DB06605,Apixaban
,34363188,area under the concentration-time curve to infinity,Apixaban area under the concentration-time curve to infinity point estimates and 90% confidence intervals were 1.03 (0.80-1.32) and 1.09 (0.85-1.41) for subjects with mild and moderate hepatic impairment vs healthy subjects.,Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34363188/),,1.03,245476,DB06605,Apixaban
,34363188,area under the concentration-time curve to infinity,Apixaban area under the concentration-time curve to infinity point estimates and 90% confidence intervals were 1.03 (0.80-1.32) and 1.09 (0.85-1.41) for subjects with mild and moderate hepatic impairment vs healthy subjects.,Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34363188/),,1.09,245477,DB06605,Apixaban
,34363188,unbound fraction,"Mean (standard deviation) apixaban unbound fraction was 6.8% (1.4), 7.9% (1.8), and 7.1% (1.3) in subjects with mild or moderate hepatic impairment and in healthy subjects.",Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34363188/),%,6.8,245478,DB06605,Apixaban
,34363188,unbound fraction,"Mean (standard deviation) apixaban unbound fraction was 6.8% (1.4), 7.9% (1.8), and 7.1% (1.3) in subjects with mild or moderate hepatic impairment and in healthy subjects.",Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34363188/),%,7.9,245479,DB06605,Apixaban
,34363188,unbound fraction,"Mean (standard deviation) apixaban unbound fraction was 6.8% (1.4), 7.9% (1.8), and 7.1% (1.3) in subjects with mild or moderate hepatic impairment and in healthy subjects.",Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34363188/),%,7.1,245480,DB06605,Apixaban
,24277644,T½,The mean T½ for apixaban alone (13.4 h) decreased to ~5 h when activated charcoal was administered at 2 or 6 h post-dose.,Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277644/),h,13.4,248372,DB06605,Apixaban
,24277644,T½,The mean T½ for apixaban alone (13.4 h) decreased to ~5 h when activated charcoal was administered at 2 or 6 h post-dose.,Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277644/),h,5,248373,DB06605,Apixaban
,34333583,flow rate,"At a flow rate of 1.0 mL min-1, the run time was around 1.8 min, which is short.",A liquid chromatography-tandem mass spectrometry method for the determination of apixaban in human plasma and its application to pharmacokinetics studies in the Indian population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34333583/),[ml] / [min],1.0,257217,DB06605,Apixaban
,34333583,run time,"At a flow rate of 1.0 mL min-1, the run time was around 1.8 min, which is short.",A liquid chromatography-tandem mass spectrometry method for the determination of apixaban in human plasma and its application to pharmacokinetics studies in the Indian population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34333583/),min,1.8,257218,DB06605,Apixaban
>,34333583,extraction recovery,"With an extraction recovery of >73% for both apixaban and apixaban 13CD3, the method was sensitive, with a limit of quantitation of 1.01 ng mL-1.",A liquid chromatography-tandem mass spectrometry method for the determination of apixaban in human plasma and its application to pharmacokinetics studies in the Indian population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34333583/),%,73,257219,DB06605,Apixaban
,28805299,area under the plasma concentration-time curve,Results Overall exposure was similar for both drugs: the geometric mean area under the plasma concentration-time curve for the 0-24-h interval was 1830 μg h L-1 for rivaroxaban and 1860 μg h L-1 for apixaban.,Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28805299/),[h·μg] / [l],1830,265908,DB06605,Apixaban
,28805299,area under the plasma concentration-time curve,Results Overall exposure was similar for both drugs: the geometric mean area under the plasma concentration-time curve for the 0-24-h interval was 1830 μg h L-1 for rivaroxaban and 1860 μg h L-1 for apixaban.,Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28805299/),[h·μg] / [l],1860,265909,DB06605,Apixaban
,28805299,area under the curve,Rivaroxaban was associated with greater inhibition of endogenous thrombin potential (geometric mean area under the curve relative to baseline during the 0-24-h interval: 15.5 h versus 17.5 h) and a more pronounced maximal prolongation relative to baseline of prothrombin time (PT) (1.66-fold versus 1.14-fold) and activated partial thromboplastin time (APTT) (1.43-fold versus 1.16-fold) at steady state than apixaban.,Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28805299/),h,15.5,265910,DB06605,Apixaban
,28805299,area under the curve,Rivaroxaban was associated with greater inhibition of endogenous thrombin potential (geometric mean area under the curve relative to baseline during the 0-24-h interval: 15.5 h versus 17.5 h) and a more pronounced maximal prolongation relative to baseline of prothrombin time (PT) (1.66-fold versus 1.14-fold) and activated partial thromboplastin time (APTT) (1.43-fold versus 1.16-fold) at steady state than apixaban.,Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28805299/),h,17.5,265911,DB06605,Apixaban
,23499913,m/,"The multiple reaction monitoring transitions used for quantification were m/z 460.20→443.27 and 460.20→198.99 for apixaban, 468.22→451.30 for [(¹³C, ²H₇]-apixaban in the electrospray positive ionization mode.",Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23499913/),,460.20,268745,DB06605,Apixaban
,23499913,m/,"The multiple reaction monitoring transitions used for quantification were m/z 460.20→443.27 and 460.20→198.99 for apixaban, 468.22→451.30 for [(¹³C, ²H₇]-apixaban in the electrospray positive ionization mode.",Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23499913/),,443.,268746,DB06605,Apixaban
,23499913,m/,"The multiple reaction monitoring transitions used for quantification were m/z 460.20→443.27 and 460.20→198.99 for apixaban, 468.22→451.30 for [(¹³C, ²H₇]-apixaban in the electrospray positive ionization mode.",Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23499913/),,460.20,268747,DB06605,Apixaban
,23499913,m/,"The multiple reaction monitoring transitions used for quantification were m/z 460.20→443.27 and 460.20→198.99 for apixaban, 468.22→451.30 for [(¹³C, ²H₇]-apixaban in the electrospray positive ionization mode.",Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23499913/),,198.99,268748,DB06605,Apixaban
,23499913,m/,"The multiple reaction monitoring transitions used for quantification were m/z 460.20→443.27 and 460.20→198.99 for apixaban, 468.22→451.30 for [(¹³C, ²H₇]-apixaban in the electrospray positive ionization mode.",Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23499913/),,468.22,268749,DB06605,Apixaban
,23499913,m/,"The multiple reaction monitoring transitions used for quantification were m/z 460.20→443.27 and 460.20→198.99 for apixaban, 468.22→451.30 for [(¹³C, ²H₇]-apixaban in the electrospray positive ionization mode.",Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23499913/),,451.30,268750,DB06605,Apixaban
less,23499913,Sample analysis time,Sample analysis time was less than 10 min including sample preparation.,Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23499913/),min,10,268751,DB06605,Apixaban
,34256392,concentration,Median concentration on admission was 205 ng/mL for rivaroxaban and 108 ng/mL for apixaban.,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),[ng] / [ml],205,269424,DB06605,Apixaban
,34256392,concentration,Median concentration on admission was 205 ng/mL for rivaroxaban and 108 ng/mL for apixaban.,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),[ng] / [ml],108,269425,DB06605,Apixaban
,34256392,t ½,"In rivaroxaban-treated patients t ½ was 17.3 hours (95% confidence interval [CI]: 15.4-19.7) without significant difference in both groups (major bleeding: t ½ 16.7 hours, 95% CI: 14.7-19.3; urgent surgery: t ½ 19.7 hours, 95% CI: 15.2-27.9; p = 0.292).",Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,17.3,269426,DB06605,Apixaban
,34256392,t ½,"In rivaroxaban-treated patients t ½ was 17.3 hours (95% confidence interval [CI]: 15.4-19.7) without significant difference in both groups (major bleeding: t ½ 16.7 hours, 95% CI: 14.7-19.3; urgent surgery: t ½ 19.7 hours, 95% CI: 15.2-27.9; p = 0.292).",Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,16.7,269427,DB06605,Apixaban
,34256392,t ½,"In rivaroxaban-treated patients t ½ was 17.3 hours (95% confidence interval [CI]: 15.4-19.7) without significant difference in both groups (major bleeding: t ½ 16.7 hours, 95% CI: 14.7-19.3; urgent surgery: t ½ 19.7 hours, 95% CI: 15.2-27.9; p = 0.292).",Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,19.7,269428,DB06605,Apixaban
,34256392,t ½,In apixaban-treated patients t ½ was 25.0 hours (95% CI: 22.9-27.6) with a longer t ½ after urgent surgery (t 1/2: 30.8 hours; 95% CI: 26.9-36.4) compared with severe bleeding (t 1/2: 20.8 hours; 95% CI: 18.8-23.2; p < 0.001).,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,25.0,269429,DB06605,Apixaban
,34256392,t 1/2,In apixaban-treated patients t ½ was 25.0 hours (95% CI: 22.9-27.6) with a longer t ½ after urgent surgery (t 1/2: 30.8 hours; 95% CI: 26.9-36.4) compared with severe bleeding (t 1/2: 20.8 hours; 95% CI: 18.8-23.2; p < 0.001).,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,30.8,269430,DB06605,Apixaban
,34256392,t 1/2,In apixaban-treated patients t ½ was 25.0 hours (95% CI: 22.9-27.6) with a longer t ½ after urgent surgery (t 1/2: 30.8 hours; 95% CI: 26.9-36.4) compared with severe bleeding (t 1/2: 20.8 hours; 95% CI: 18.8-23.2; p < 0.001).,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,20.8,269431,DB06605,Apixaban
,30918237,peak PC,A total of 73 off-label under-dose users of rivaroxaban (37% of all users and 63% of lower dose users) had acceptable peak PC (155-400 ng/mL).,Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30918237/),[ng] / [ml],155-400,270029,DB06605,Apixaban
,30918237,peak PC threshold,"Additionally, 46 off-label under-dose users of apixaban (31% of all users and 55% of lower dose users) received appropriate doses according to peak PC threshold (90-386.4 ng/mL).",Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30918237/),[ng] / [ml],90-386.4,270030,DB06605,Apixaban
,31236790,half-maximal inhibitory concentration (IC50),The population mean of half-maximal inhibitory concentration (IC50) of apixaban was estimated to be 45.3 ng/mL.,Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31236790/),[ng] / [ml],45.3,271444,DB06605,Apixaban
,31236790,BASE,"The population mean of BASE and Imax value were estimated to be 40.2 and 38.4 nmol/min/mg protein, respectively.",Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31236790/),[nM] / [mg·min],40.2,271445,DB06605,Apixaban
,31236790,Imax,"The population mean of BASE and Imax value were estimated to be 40.2 and 38.4 nmol/min/mg protein, respectively.",Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31236790/),[nM] / [mg·min],38.4,271446,DB06605,Apixaban
